The cancer-promoting proteins (NCBP2, AMD, MER34, ENC1, and COA4) were suppressed, while the secretory glycoprotein (A1BG) and ROS-reducing protein (ASB6) were overexpressed in the treatment group. This evidence concerns the gene ASB6 and cancer.